HIELUX
Advisory
Supplier Intelligence Report
Syringes & Needles
Asia-Sourced · NL · BE · Rotterdam Hub
Prepared exclusively for
June 26, 2026
Hielux Advisory · Singapore
Freight validity
14 days from issue
Classification
Client-use only
Distribution
Not for redistribution
Executive Summary
Three findings. One path forward.
Recommendation
Kangyou Medical
$0.0183/unit landed · CE MDR to 2030
Est. annual saving
$56K–$108K
vs current market
One open item
INI — full MDR cert pending
Finding 01 — Regulatory
Kangyou holds CE MDR valid until March 2030 — the strongest certification standing in this report. Combined with the lowest landed cost for standard disposables, it is the primary recommendation for this profile.
Finding 02 — Specialisation
Yesomed (subsidiary of Shenzhen-listed Suzhou Tianhua, code 300390) is the only supplier in this report that makes safety and auto-disable syringes with full CE MDR and ISO 13485 standing, backed by WHO PQS for auto-disable and a globally audited quality system. For EU safety-syringe and auto-disable lines, no other supplier in this report qualifies.
Finding 03 — Entry Point
INI Medical offers the lowest MOQ (100,000 units) and the broadest product range, at the second-lowest standard syringe pricing in this report — behind Kangyou. Suitable for a trial order. CE MDR transition was approved May 2024; we confirmed the current certificate status directly with the manufacturer, and the supporting documentation is provided with this report.
Primary Risk
INI Medical's MDR transition status is the only unresolved regulatory question in this report. Every other supplier's certification was verified as current against public records. We confirmed its current status directly with the manufacturer; the full MDR certificate is pending issuance and its documentation accompanies this report.
Recommended strategy for this profile
Primary
Kangyou — standard disposables, MDR 2030, lowest landed cost
Safety lines
Yesomed — safety & auto-disable syringes, WHO PQS, CE MDR
Trial / Entry
INI Medical — low MOQ pilot, pending full MDR cert
Needles / Backup
Qiaosend — needle sourcing, backup supply, export-only structure
Client Profile
Who this report was built for
Location
Rotterdam, Netherlands
Channel
Hospital group procurement — NL & BE
Products
Single-use syringes, safety needles, insulin syringes
Annual Volume
~2.5 million units across SKUs
Key Requirements
CE MDR-compliant manufacturers · ISO 13485 audited by recognised body · EO sterilisation with ISO 11135 validation documentation available · Minimum 2 qualified backup suppliers · FOB pricing with CIF Rotterdam calculation including EU ETS
Verification Methodology
What was verified. What was not.
Every claim in this report is sourced. Where verification was not possible or not performed, that is stated explicitly. A report that tells you only what it found is less valuable than one that also tells you what it could not confirm.
Hielux Advisory holds no commercial relationship with any manufacturer in this report. No referral fee, commission, or compensation of any kind was received or solicited. Every assessment reflects independent evaluation against this client's profile only.
Verified
Direct supplier engagement
Each shortlisted supplier maintains a named account contact assigned to Hielux's category inquiries. Pricing, MOQ, lead times, payment terms, and certification documentation were obtained directly through these contacts via written correspondence and video calls during the evaluation period. No supplier was informed of this report or its intended recipient in advance.
Certification cross-reference
CE MDR, FDA (K053519), ISO 13485, and WHO PQS (E008) verified against issuing body records and WHO PQS public database. All further national registrations were confirmed via manufacturer documentation and public registries.
Parent company verification
Yesomed confirmed as wholly-owned subsidiary of Suzhou Tianhua Super Clean Technology Co., Ltd. (Shenzhen Stock Exchange: 300390). Registered capital RMB 60 million confirmed via public filings.
Freight and landed cost
Ocean freight rates were sourced from the Drewry World Container Index (week of June 25, 2026). EU ETS surcharges were cross-referenced against carrier market rates published by Searoutes and CMA CGM (2026, full ETS phase-in basis).
Documentation obtained & included
Original certificates, current scope documents, declarations, and current compliance status were obtained directly from each manufacturer, verified against issuing-body and public records, and are included with this report. Hielux re-verifies on renewal or scope change.
Recommended before large-volume commitment
Physical factory audit
No on-site inspection was conducted. Physical GMP audit should be commissioned independently before large-volume commitment. Recommended for orders above USD 50,000.
EO sterilisation validation records
EO sterilisation was confirmed as the method used. The ISO 11135 validation file — sterilisation cycle validation, bioburden data, sterility assurance level records — is collected from the manufacturer during sample qualification, which Hielux coordinates.
Production batch quality
Sample quality evaluated for Yesomed only. Pre-production sample evaluation recommended for all other suppliers before first commercial order.
Evaluation Process
How we arrived at these four.
These manufacturers were not the only ones considered. From a broader pool identified across Asia in this product category, six were shortlisted for detailed evaluation against this profile. Of those six, four met the criteria in full.
6
Evaluated against profile
Full review
4
Met criteria in full
Presented below
1
Did not meet criteria
See Not Recommended
Procurement Scorecard
| Supplier |
MDR Standing |
Reg. Risk |
FOB Price |
MOQ Flex. |
Cert. Depth |
Product Breadth |
Best Use |
| Yesomed |
B+ |
Low |
C |
B |
A |
A |
Safety / auto-disable / WHO PQS |
| INI Medical |
C* |
Medium* |
A |
A |
B |
A |
Trial orders / broad range |
| Kangyou |
A |
Low |
A |
B |
B |
B |
Standard primary supplier |
| Qiaosend |
B+ |
Low |
B |
A |
B |
B |
Needles / backup source |
* INI Medical MDR transition in progress — current status confirmed directly with the manufacturer; documentation enclosed. A = Strong, B = Adequate, C = Weaker relative to this profile. Reg. Risk reflects certification certainty for EU hospital supply.
Supply Chain Overview
Origin to Rotterdam — four supplier lanes
All four suppliers ship to Rotterdam via established Asia–North Europe container lanes. Transit times and port selection vary by supplier location. Sea freight rates reflect Drewry WCI June 2026.
Supplier
Origin Port
Transit
Destination
Kangyou MedicalPrimary · Standard syringes
→
→
Cape of Good Hope
35–45 days
→
Rotterdam
ECT · Maasvlakte
Wuxi YesomedPrimary · Safety lines
→
→
Cape of Good Hope
35–45 days
→
Rotterdam
ECT · Maasvlakte
INI MedicalConditional · MDR pending
→
→
Cape of Good Hope
35–45 days
→
Rotterdam
ECT · Maasvlakte
Qiaosend MedicalBackup · Needles
→
→
Cape of Good Hope
38–48 days
→
Rotterdam
ECT · Maasvlakte
Secondary / conditional lane
Freight reference — Shanghai / Ningbo to Rotterdam · June 2026
EU ETS surcharge
$168 / 40HQ
Qingdao to Rotterdam is approximately $50–80 per 40HQ above Shanghai rates on the same lane due to port positioning. As of June 2026, Cape of Good Hope is the standard routing for Asia–North Europe: Red Sea / Suez transit remains largely suspended after Houthi attacks resumed in early 2026, with carriers (led by CMA CGM) only selectively returning to the Suez lane as conditions allow. Cape routing adds roughly 10–14 days versus the pre-disruption Suez transit. Spot rates sit at peak-season levels (mid-2026 GRIs and PSS in force) and are volatile — confirm routing, transit time, and surcharges with your freight forwarder at booking.
Price Comparison
All four factories, side by side.
Factory-direct FOB pricing for the standard disposable and insulin lines — the products all four suppliers make. The lowest price in each row is highlighted. Specialty lines (auto-disable, safety, needles) sit in each supplier's own section, since not every factory produces them.
| FOB / unit · USD |
Kangyou | INI Medical | Yesomed | Qiaosend |
| 1 ml | $0.0145 | $0.0200 | $0.024 | $0.022 |
| 3 ml | $0.0145 | $0.0165 | $0.022 | $0.0225 |
| 5 ml | $0.0153 | $0.0175 | $0.023 | $0.023 |
| 10 ml | $0.022 | $0.0258 | $0.031 | $0.034 |
| 20 ml | $0.0356 | $0.0395 | $0.043 | $0.050 |
| 50 ml | $0.088 | $0.099 | — | $0.125 |
| Insulin 0.5 / 1 ml | $0.0235 | $0.028 | $0.030 | $0.032 |
All prices FOB (factory-direct, USD). — = size not offered by that supplier. Kangyou is lowest in every standard size — the basis for its primary recommendation. Delivered cost (CIF Rotterdam) follows on the next page.
Landed Cost
From factory quote to delivered cost.
FOB is the factory quote. What you actually pay is the landed cost — FOB plus ocean freight, EU ETS and insurance to CIF Rotterdam. Because all four ship the same China–North Europe lane, the freight add is roughly the same for each (about $0.0038 per unit at full-container volume) — so the cheapest quote stays the cheapest delivered.
3 ml standard · CIF Rotterdam · per unit · June 2026
| Supplier | FOB | + ship · ETS · ins | CIF · full 40HQ | CIF · trial (LCL) |
| Kangyou | $0.0145 | +$0.0038 | $0.0183 | $0.0197 |
| INI Medical | $0.0165 | +$0.0038 | $0.0203 | $0.0229 |
| Yesomed | $0.022 | +$0.0038 | $0.0258 | $0.0273 |
| Qiaosend | $0.0225 | +$0.0038 | $0.0263 | $0.0289 |
Full-container (40HQ) basis · freight $4,392/40HQ + EU ETS $168 + insurance 0.3% · June 2026. Trial-order (LCL) cost is higher per unit because small shipments pay more freight per CBM.
Landed cost per unit · full 40HQ · CIF Rotterdam
What the numbers say
For standard disposable syringes with full MDR compliance, Kangyou is the primary recommendation. For safety syringes and auto-disable (WHO PQS) lines, Yesomed is the only option in this report. For a low-MOQ trial order, INI Medical — subject to MDR confirmation. For needles and backup supply, Qiaosend. These four are not interchangeable — they serve different parts of a supply chain.
* INI Medical MDR transition approved May 2024 — current status confirmed directly with the manufacturer; documentation provided with this report.
Savings Analysis
What this means in dollars.
What this assumes
Volume and SKU mix follow the client profile on page 03. Current spend is estimated against aggregate third-party EU import benchmarks for Chinese-manufactured disposable medical devices. New spend uses verified factory-direct pricing from the four shortlisted suppliers. A tailored client report uses the buyer's actual SKU breakdown and current supplier pricing for precise calculation.
Current annual spend
$108K – $160K
Estimated · market benchmark midpoints
New annual spend
$52,000
Verified · cost-optimized allocation
Saved annually
$56,000 – $108,000
Against report cost of $1,500 · payback within first order cycle
Breakdown by SKU category
| SKU category |
Volume |
Market range |
Recommended |
Y1 savings |
| 3ml standard syringe |
1,200,000 |
$0.040 – $0.060 |
Kangyou · $0.0183 |
$26K – $50K |
| 5ml standard syringe |
400,000 |
$0.045 – $0.065 |
Kangyou · $0.0193 |
$10K – $18K |
| 10ml standard syringe |
200,000 |
$0.060 – $0.085 |
Kangyou · $0.0275 |
$6K – $11K |
| 1ml insulin syringe |
300,000 |
$0.050 – $0.075 |
Kangyou · $0.0299 |
$6K – $14K |
| Safety syringe 3ml |
200,000 |
$0.060 – $0.090 |
Yesomed · $0.0269 |
$7K – $13K |
| Standard hypodermic needle |
200,000 |
$0.015 – $0.025 |
Yesomed · $0.0125 |
$1K – $2K |
Market benchmark derived from US Census Bureau and Eurostat HS 9018.31 import data (2023), adjusted to reflect third-party distributor pricing — excludes pharma intercompany transfers and private-label offshore IP structures. Savings are gross of switching costs, transition timelines, and working capital adjustment, and are rounded to the nearest $1,000. Allocation strategy follows.
Allocation Strategy
Two ways to deploy these findings.
The four shortlisted suppliers can be deployed under two distinct procurement strategies. Each optimizes for a different priority. The right choice depends on the buyer's operational maturity, supply chain risk tolerance, and forward sourcing strategy.
Strategy A
Cost-optimized
SKU-by-SKU matching to lowest-cost qualified supplier. Maximum landed-cost savings.
Allocation
Standard disposables + insulin · Kangyou
Safety syringes + needles · Yesomed
Broad-range / low-MOQ · INI Medical (post-MDR)
Backup / needle alternative · Qiaosend
Estimated annual
~$52,000
$56K – $108K saved vs current market
Trade-offs
Four supplier relationships to manage · separate QA processes · separate EUAR coordination per origin · best per-unit pricing on every SKU
Strategy B
Operationally-simple
Concentrated primary supplier with one backup. Slight cost premium for operational simplicity and supply chain priority.
Allocation
Primary (~70%) · Yesomed
covers every SKU type — standard, safety, auto-disable and insulin — under one CE MDR + ISO 13485 + WHO PQS cert stack
Backup (~30%) · Kangyou
cost backstop on standard disposables; MDR-confirmed
Estimated annual
~$64,000
$44K – $96K saved vs current market
Trade-offs
Two supplier relationships · one primary supplier covers every SKU type under a single CE MDR / ISO 13485 cert stack · supply chain priority during constraints · ~$12K higher annual cost
Which strategy fits
Strategy A suits buyers with mature procurement infrastructure who can manage four supplier relationships and want maximum per-unit savings. Hospital procurement groups with established EU MDR processes typically operate here.
Strategy B suits buyers with leaner procurement teams who prefer to consolidate every SKU type with one qualified primary supplier, or supply chains where stockout risk carries higher commercial cost than the ~$12K per-year premium. Distributors who value a single primary relationship over per-SKU price optimisation typically operate here.
Supplier 01 of 04
Kangyou Medical
Changzhou, Jiangsu Province, China · FOB Shanghai · en.kym.cn
Best fit: Standard disposable syringes · Primary EU MDR-compliant supplier · Lowest landed cost
CE MDR · Valid March 2030
ISO 13485
EU Authorised Representative: Shanghai International Holding Corp. GmbH, Europe. Total facility 66,700m², Class 100,000 cleanroom 15,000m². Product range includes CE MDR-certified surgical staplers (anorectal, linear, tube, skin) — quality management system tested across more complex device categories than syringe-only factories. Rated AAA credit grade by Changzhou authorities.
| Size | FOB/unit | MOQ |
|---|
| 0.5ml / 1ml | $0.0235 | 200,000 |
Sales contact — Shirley
Provided upon engagement
FOB Port — Shanghai
Supplier 01 · Assessment
Kangyou Medical
Changzhou, Jiangsu · FOB Shanghai
Profile
Kangyou carries the strongest regulatory standing in this report — CE MDR valid until March 2030, EUAR held by Shanghai International Holding Corp. GmbH in Europe. That is a fully structured EU compliance chain. Their manufacturing scope extends to CE MDR-certified surgical staplers alongside syringes, infusion sets, and blood transfusion sets. A factory that produces certified surgical staplers operates a quality management system tested against more complex device categories than syringe-only manufacturers. Rated Changzhou AAA credit-grade enterprise. Communication responsiveness was consistent throughout evaluation. Direct supplier engagement conducted independently.
The economic case
Lowest FOB pricing for standard disposable syringes in this report — $0.0145/unit on 3ml FOB Shanghai. Strongest MDR standing. At full 40HQ volume, landed cost to Rotterdam is $0.0183/unit. For a distributor whose primary requirement is standard disposable syringes for EU hospital procurement, this is the primary recommendation in this report. Pricing at MOQ stage is fixed. Volume contract terms — including price adjustment, priority allocation, and extended payment flexibility — are available through a documented commitment with defined quantity and timeline.
Financial standing note
Kangyou has been rated Changzhou AAA credit-grade enterprise and holds the "Jiangsu Medical Device Manufacturing Enterprises Integrity Unit" designation. For buyers conducting supplier financial due diligence, these are verifiable public designations. For orders above USD 50,000, a full financial due diligence check is recommended independently of this report.
Sales contact — Shirley
Provided upon engagement
FOB Port — Shanghai
Supplier 02 of 04
Wuxi Yesomed
Wuxi, Jiangsu Province, China · FOB Shanghai · en.chinasyringe.com
Best fit: Safety & auto-disable syringes · WHO PQS · deepest certification stack
CE MDR
ISO 13485
FDA · K053519 · Since 2006
WHO PQS · E008 · AD syringe
+ registered in 100+ markets
Wholly-owned subsidiary of Suzhou Tianhua Super Clean Technology Co., Ltd. (Shenzhen Stock Exchange: 300390). Registered capital RMB 60 million. Factory 50,000m², clean workshop 11,000m². 24 domestic patents (11 invention, 13 utility model) + patents in USA, Europe, India, Indonesia, PCT. Products exported to approximately 100 countries.
MOQ — Syringes
200,000 units
MOQ — Needles
1,000,000 units
Lead time
30 days from deposit
Payment terms
30% deposit · 70% before shipment
FDA clearance
K053519 · Safety syringe · since 2006
WHO PQS
Auto-disable syringe only · PQS E008
Annual production capacity
Self-destructing
600 million units
Safety syringes
500 million units
Standard disposable
400 million units
Insulin syringes
200 million units
High-pressure syringes
4 million units
Surgical instruments
2 million sets
Wuxi Yesomed · Pricing
FOB Shanghai · All prices USD · EO sterilised · Latex-free · Medical-grade PP
Auto-Disable (AD) · WHO PQS E008 Certified
| Size | FOB/unit | MOQ | Carton |
|---|
| 0.05ml | $0.025 | 200,000 | 3,000 |
| 0.5ml | $0.020 | 200,000 | 3,000 |
| Size | FOB/unit | MOQ | Carton |
|---|
| 1ml | $0.028 | 200,000 | 3,000 |
| 3ml | $0.0205 | 200,000 | 2,400 |
| 5ml | $0.0215 | 200,000 | 2,000 |
| 10ml | $0.033 | 200,000 | 1,600 |
Insulin Syringes · MDR · ISO 13485
| Size | FOB/unit | Size | FOB/unit |
|---|
| 0.3ml | $0.032 | 1ml | $0.030 |
| 0.5ml | $0.030 | — | — |
Needles · FDA · MDR · ISO 13485
| Product | Gauge | FOB/unit | MOQ |
|---|
| Safety needle | 18G–30G | $0.022 | 1,000,000 |
| Standard needle | 18G–30G | $0.007 | 1,000,000 |
| Insulin pen needle | 29G–32G | $0.019 | 200,000 |
Safety and standard needle MOQ is 1,000,000 units. Insulin pen needle MOQ is 200,000 units.
All prices FOB Shanghai. WHO PQS covers auto-disable syringe (E008) only — does not extend to needles or standard disposable lines. High-pressure syringes (imaging use) available — request pricing separately. 2-Part Luer Slip available on request at marginally lower pricing.
Supplier 02 · Assessment
Wuxi Yesomed
Wuxi, Jiangsu · FOB Shanghai · Subsidiary of Shenzhen-listed Suzhou Tianhua (300390)
Profile
Yesomed's legal entity is Wuxi Yushou Medical Appliances Co., Ltd., a wholly-owned subsidiary of Suzhou Tianhua Super Clean Technology — Shenzhen-listed (code 300390) since 2014, which acquired Wuxi Yushou in 2015. That parent structure provides financial stability and audit trail that privately-held factories cannot offer. Initial contact requires persistence. Once established, the relationship is consistent — documentation, samples, and responses arrive without delay. Communication responsiveness remained consistent throughout all document and sample requests during evaluation.
Certification depth
Yesomed's regulatory clearances span more markets than any other supplier in this report. FDA clearance K053519 has been current since 2006. WHO PQS E008 covers auto-disable syringes — this certification is specific to that product line only and does not extend to needles or standard disposables. Its globally audited quality system — held by only a small fraction of Chinese manufacturers and certified well beyond the EU baseline — underwrites the CE MDR and ISO 13485 standing that matters for EU supply. For a distributor whose channel requires safety-syringe compliance for EU hospital procurement, no other supplier in this evaluation matches this depth.
Where to use them
Safety syringes — AD, RUP, and safety clip — are this factory's core capability. Their annual safety syringe capacity of 500 million units and 24 domestic patents reflect sustained investment in this specific technology. For standard luer lock at volume, Kangyou delivers a lower landed cost. For safety lines, imaging (high-pressure) syringes, or any line requiring WHO PQS auto-disable certification, Yesomed is the appropriate first call. Volume contract pricing is negotiable through a documented commitment — not at MOQ inquiry stage.
Sales contact
Provided upon engagement
FOB Port — Shanghai
Supplier 03 of 04
Zhejiang INI Medical
Wenzhou, Zhejiang Province, China · FOB Ningbo / Shanghai · inimd.com
Best fit: Low-MOQ trial orders · Broad product range including biopsy and aesthetic needles
CE MDR
ISO 13485 · TUV Rheinland Audited
MDR transition — status confirmed with manufacturer
MDR transition approved May 2024. Full MDR certification expected 2026. Current certificate status and number were confirmed directly with the manufacturer; the supporting documentation accompanies this report. MDD certificate expired November 2025 — though under the EU 2023/607 transition, a legacy MDD certificate backed by an MDR application filed by May 2024 is generally deemed valid to 2027–2028, subject to conditions. ISO 13485 audited by TUV Rheinland. 26,000m² facility, 8,000m² Class 100,000 cleanroom. 400+ employees. Annual output RMB 150 million (2024).
| Size | FOB/unit | Size | FOB/unit |
|---|
| 1ml | $0.027 | 5ml | $0.028 |
| 3ml | $0.027 | 10ml | $0.041 |
Insulin Syringes & Pen Needles · MOQ 100,000
| Product | FOB/unit |
|---|
| Insulin syringe 0.5ml / 1ml (U-40 / U-100) | $0.028 |
| Insulin pen needle 29G–32G (4/5/6mm) | $0.015 |
Sales contact — Elena
Provided upon engagement
Port — Ningbo / Shanghai
Supplier 03 · Assessment
Zhejiang INI Medical
Wenzhou, Zhejiang · FOB Ningbo / Shanghai
Profile
INI Medical's widest differentiator is product breadth. Alongside standard and safety syringes, their catalogue includes Tru-Cut biopsy needles, aesthetic medicine cannulas (sealed-circle side-hole design for filler injection procedures), insulin pen needles in three lengths (4/5/6mm, 31G–32G), vaccine syringes, and needle cannulas. A distributor whose product mix extends beyond basic injection devices can consolidate more sourcing here than with any other supplier in this evaluation. ISO 13485 is audited by TUV Rheinland — an internationally recognised body with independent audit credibility. 20+ quality tests per batch with 100% needle sharpness and patency inspection. Communication responsiveness was consistent throughout evaluation.
MDR status — conditional recommendation
MDR status — confirmed directly with the manufacturer
INI Medical's CE MDR transition was approved May 2024. Full MDR certification is expected in 2026. Their MDD certificate expired November 2025 — though under the EU 2023/607 transitional provisions, a legacy MDD certificate backed by an MDR application filed by May 2024 is generally "deemed valid" through 2027–2028. For Dutch and Belgian hospital tenders where MDR compliance is a contractual requirement, we confirmed the current certificate status directly with the manufacturer before issuing this report, and the supporting documentation is enclosed. Should the certificate be reissued or its scope change after this date, Hielux will obtain the updated document on the client's behalf.
Where to use them
Second-lowest standard syringe pricing in this report ($0.0165/unit, 3ml FOB — behind Kangyou's $0.0145) and lowest MOQ at 100,000 units. Once the full MDR certificate issues, INI Medical is suitable as a secondary supplier for standard disposables and a primary source for the specialised needle categories no other supplier in this report covers. Volume contract terms are available with documented commitment — not at first inquiry stage.
EO sterilisation documentation
EO sterilisation is confirmed across all INI Medical product lines. The ISO 11135 validation documentation — cycle validation reports, bioburden data, and sterility assurance level (SAL) records — is collected from the manufacturer during sample qualification, which Hielux coordinates. This documentation is standard for EU hospital procurement and is prepared ahead of tender submission.
Sales contact — Elena
Provided upon engagement
Port — Ningbo / Shanghai
Supplier 04 of 04
Qiaosend Medical
Zibo, Shandong Province, China · FOB Qingdao · qiaosend.com.cn
Best fit: Needle sourcing · Backup supply line · Low-MOQ entry · Export-specialist structure
CE MDR · Valid July 2029
ISO 13485
Sino-US joint venture. Subsidiary of Shandong Qiaopai Group Co., Ltd. Registered capital USD 3.5 million. EU Authorised Representative: MedNet EC-REP GmbH. EO sterilisation. Export-only operation — domestic China market handled separately by parent Qiaopai entity. Established 2006. Cleanroom 10,000m². Supplies 30+ countries across Europe, Middle East, South America, Southeast Asia, Africa.
Needles — most competitive pricing in this report
| Product | FOB/unit | MOQ |
|---|
| Hypodermic needle 18G | $0.009 | 100,000 |
| Hypodermic needle 19G–27G | $0.0085 | 100,000 |
| Insulin syringe 0.5ml / 1ml | $0.032 | 200,000 |
Assessment
Qiaosend's structure is the distinguishing factor. Built as an export-only joint venture from inception, their compliance infrastructure was not adapted from a domestic manufacturing model — it was designed for international supply from the start. CE MDR valid July 2029, EUAR with MedNet EC-REP GmbH. Standard syringe pricing is higher than Kangyou and INI Medical for comparable SKUs, but needle pricing is the most competitive in this report. The appropriate positioning for this profile is secondary supplier for needles and backup supply line for syringes. MOQ of 100,000 units provides accessibility for trial orders.
Sales contact — Merlin
Provided upon engagement
FOB Port — Qingdao
Evaluated · Not Recommended
Guangdong Haiou
Guangdong Haiou Medical Apparatus Co., Ltd. · Puning City, Guangdong
FOB Shantou · haiou.net.cn
Did not meet profile criteria
01
MOQ Mismatch
500,000 unit minimum — 2.5× above profile requirement
For a first order with an unverified supplier, this cash commitment is disproportionate to the profile requirements and appropriate risk tolerance at initial engagement stage.
02
No Direct Relationship
Evaluation based on price sheet only — no engagement conducted
No direct communication, no named contact engagement, no sample evaluation. Hielux does not recommend suppliers where direct independent engagement has not occurred prior to the report.
03
Port Limitation
FOB Shantou — limited direct service to Rotterdam
Fewer direct vessel services to Rotterdam than Shanghai, Ningbo, or Qingdao. Transit reliability and carrier selection are materially more limited on this lane.
Certifications held
FDA · WHO PQS · CE · ISO 13485
Relationship status
Price sheet only · no direct contact
Conditions for reconsideration
Haiou's certification stack — FDA, WHO PQS, CE, ISO 13485 — is solid. If direct supplier engagement is established, samples are evaluated, and order volume justifies 500,000 units, Haiou becomes viable, particularly for safety syringe lines where their pricing is competitive at scale.
First Order Reference
Typical first order timeline — Asia to Rotterdam
Timelines are indicative only. Actual schedules vary by supplier responsiveness, sample evaluation duration, and production scheduling.
Day 1–3
Initial contact. NDA if required. Confirm product specifications and request proforma invoice.
Day 4–10
Sample dispatch from factory. Courier charges paid by buyer. One sample order standard — product typically at no cost.
Day 11–20
Sample evaluation against specification. ISO 11135 sterilisation documentation review. Clinical team sign-off if required.
Day 21–35
Final quotation. Purchase order issued. Deposit transferred (typically 30%). MOQ pricing is fixed at this stage.
Day 36–65
Production. 30 days standard lead time from deposit receipt. Balance payment (70%) due before shipment.
Day 66–110
Sea freight — Shanghai/Ningbo to Rotterdam via Cape of Good Hope. 35–45 days transit. LCL or FCL by volume.
Day 111–120
Customs clearance Rotterdam. Import duty, VAT, and EORI requirements are buyer responsibility — verify with customs broker before shipment. Delivery to warehouse.
Next Steps
What to do now — and how Hielux can help.
Your immediate actions
01
First · INI Medical
Review the INI Medical CE MDR certificate provided with this report — status confirmed directly with the manufacturer, product scope covering your SKUs. The full MDR certificate is pending issuance; Hielux will deliver it the moment it issues and flag any change before your PO.
02
First · Kangyou
Request Kangyou samples for your primary SKUs (3ml, 5ml, 10ml luer lock). Specify your product requirements in writing — material spec, packaging, labelling — to receive the correct sample configuration.
03
Parallel · Yesomed
If safety syringes are in your product range, initiate Yesomed qualification in parallel. Request AD and RUP samples; the EU MDR and ISO 13485 documentation is already provided with this report.
04
Medium term
Designate Qiaosend as backup needle supplier. Confirm needle specifications and request a sample order. This relationship can be maintained at low effort as a qualified backup source.
05
Before first PO
The current CE certificates (with scope confirmation) are provided with this report. Before your first PO, request the proforma invoice from the supplier — and do not transfer the deposit without a signed PI in hand.
From here, Hielux can manage
Supplier qualification — sample coordination and testing against your specs. (Certificates in this report are already verified; Hielux re-checks on renewal or scope change.)
Volume contract structuring — defined quantity and timeline to open pricing that doesn't exist at first-order stage.
Sourcing engagement — we manage communication, negotiation and order coordination on your behalf.
Ongoing supply-chain management — repeat orders, pricing reviews, backup activation and market intelligence.
Email
advisory@hieluxmt.com
Appendix
Incoterms, scope & disclaimer
Incoterms reference
FOB — Free On Board
Seller delivers goods onto the vessel at origin port. Buyer assumes all costs and risk from that point — ocean freight, insurance, destination charges, import duties. All prices in this report are FOB.
CIF — Cost, Insurance & Freight
Seller pays ocean freight and insurance to the destination port. Buyer assumes risk once goods are loaded at origin but seller arranges and pays for transit. All landed cost calculations in this report are CIF Rotterdam.
LCL — Less than Container Load
Shipment shares container space with other cargo. Charged per CBM (cubic metre). Used for MOQ-level orders. Higher per-unit freight cost than FCL. Suitable for trial orders and initial qualification shipments.
FCL — Full Container Load
Entire container dedicated to one shipment. Charged per container. Lower per-unit freight cost. 40HQ (high-cube 40-foot) is the standard container used for medical consumables — approximately 76 CBM usable volume.
EU ETS Surcharge
Carrier surcharge for EU Emissions Trading System compliance on voyages involving EU ports. Rate used: $168 per 40HQ and ~$25 per LCL shipment — current market rate confirmed by Searoutes and CMA CGM (2026, Asia–North Europe lane — full ETS phase-in). Rates are revised quarterly by carriers. Verify with freight forwarder at booking.
DDP — Delivered Duty Paid
Seller delivers goods to buyer's premises, all costs and duties paid. Not the default terms for suppliers in this report — all pricing is FOB. DDP is available from some suppliers on request and typically adds 8–15% to FOB price on this lane.
Scope of this report
CIF Rotterdam is the boundary of this report
This report covers supplier evaluation, FOB pricing, and landed cost calculation to CIF Rotterdam. Import duties, customs clearance, EORI registration, VAT, and any post-arrival logistics are the buyer's responsibility and outside the scope of this engagement. Buyers should verify applicable import duties and trade measures with their customs broker before placing orders. Note: the EU's International Procurement Instrument measure on Chinese medical devices (in force since June 2025) can cap Chinese-origin content in EU public-procurement tenders at or above €5 million — material where the supply feeds public hospital tenders.
Disclaimer
All pricing, certification status, MOQ, lead time, and freight data was sourced directly from named supplier representatives and verified against available public records at the time of preparation (June 2026). Certifications remain subject to renewal, suspension, or scope change after that date; Hielux re-verifies on renewal. Freight rates reflect live market data at time of publication and are subject to change without notice. Hielux Advisory makes no warranty as to the fitness of any supplier for any specific regulatory, clinical, or commercial purpose, and assumes no liability for decisions made on the basis of this report. Factory audit and legal review are the buyer's responsibility prior to commercial engagement. This report is prepared for the named client only and is not intended for redistribution or resale. Hielux Advisory holds no financial interest in any manufacturer featured in this report.
Hielux Advisory · Confidential · Client-use only
June 2026 · Freight valid 14 days · Identifying client and supplier details have been redacted or substituted for this published example.
Download PDF